UBS Group’s Structure Therapeutics GPCR Stock Holding History
Bought
Maintained
Sold
Other funds holding GPCR
BBA
UBS Group's GPCR Position: Q3 2026 in Review
UBS Group reduced its Structure Therapeutics (GPCR) stake by 12% in Q3 2026, selling an estimated $2.2M and leaving 332,122 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3360.
UBS Group first reported a position in GPCR in Q2 2023 and has held it in 13 quarters since. The position peaked at $20.3M in Q2 2026. 172 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.
- UBS Group held 332,122 shares of Structure Therapeutics worth $10.4M as of Q3 2026.
- UBS Group sold 46,864 Structure Therapeutics shares in Q3 2026, an estimated $2.2M.
- Structure Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #3360 holding.
- UBS Group first reported a position in Structure Therapeutics in Q2 2023 and has held it in 13 quarters since.
- UBS Group's Structure Therapeutics position peaked at $20.3M in Q2 2026.
- 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.